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Introduction
Traumatic brain injury (TBI) is a major public health crisis. An 
estimated 1.4 million people incur a TBI annually; a rate of 1 
injury every 23 seconds.1 The resulting incidence rate is approxi-
mately 100 per 100,000 US citizens and is respectively 8 and 34 
times higher than breast cancer and HIV/AIDS diagnoses each 
year.2 Military personnel, particularly those serving in Afghanistan 
and Iraq are a special population highly susceptible to TBI as blasts 
are the primary cause of injury for this group.3 Sports related head 
injuries are also becoming more common and it is estimated that 
300,000 such injuries occur annually.1 Despite these staggering 
statistics, no clinically effective pharmacological treatments exist 
to aid recovery during the acute or secondary stages of injury.4-6
A prevalent issue in the field of TBI research is the number of 
therapeutic compounds that have initially proven experimentally 
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promising, but then do not translate clinically. It has been stated 
that there is a gap between the bench to the bedside.5 In other 
words, inconsistencies exist between preclinical testing in the 
laboratory and the clinic. The gaps most relevant to experimen-
talists are: treatment window and duration.4 For animal models 
the treatment window (in which the pharmacotherapy begins) 
is approximately less than an hour while clinically it is usually 
four to eight hours; while treatment durations can be over several 
days. Surprisingly few studies have examined continuous dosing 
regimens in TBI. Subcutaneous osmotic mini-pumps were used 
in order to deliver the immunosuppressant cyclosporine A (CsA) 
following cortical contusion injury (CCI).7 In a second study, a 
single bolus intraperitoneal (i.p.) injection, as a loading dose, was 
administered 15 mins post-CCI followed by chronic infusion of 
CsA. In another study, nicotine was infused continuously follow-
ing TBI and it was shown to attenuate nicotinic receptor deficits 
previously,  we  have  demonstrated  that  nicotinamide  (NAM),  a  neuroprotective  soluble  B-group  vitamin,  improves 
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beneficial following continuous infusions over 7 days post-TBI. The purpose of this study was to investigate the preclinical 
efficacy of NAM treatment as it might be delivered clinically; over several days by slow infusion. Rats were prepared with 
either unilateral controlled cortical impact (CCI) injuries or sham procedures and divided into three groups: CCI-NAM, CCI-
vehicle and sham. Thirty minutes following CCI, Alzet osmotic mini-pumps were implanted subcutaneously. NAM was 
delivered at a rate of 50 mg/kg/day for 7 days immediately post-CCI. On day 7 following injury, the pumps were removed 
and blood draws were collected for serum NAM and nicotinamide adenine dinucleotide (NAD+) analyses. starting on 
day 2 post-CCI, animals were tested on a battery of sensorimotor tests (bilateral tactile adhesive removal, locomotor 
placing and limb-use asymmetry). Continuous infusion of NAM resulted in a significant serum elevation in NAM, but not 
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and thus need to be examined preclinically. Since continuous i.v. 
infusion into awake, behaving rodents is problematic at best, 
the alternative is the use of subcutaneous osmotic mini-pumps. 
Therefore, the main purpose of this study was to investigate the 
preclinical efficacy of NAM treatment at a targeted delivery rate 
of 0.625 mg/hr (to achieve 50 mg/kg), as it would be delivered 
clinically; over several days by slow, continuous infusion.
Results
NAM and NAD+ analysis. Two separate one-way ANOVAs 
were conducted to analyze NAM and NAD+ blood serum levels 
(µg/mL). Three levels were used in this analysis (NAM-treated, 
vehicle-treated and sham). There was a statistically significant 
difference between the three groups in terms of NAM blood 
serum levels, F(2,20) = 3.81, p = 0.04 (see Fig. 1). Pairwise 
comparisons  revealed  significant  differences  in  serum  NAM 
levels [LSD(15) = 5.00, p = 0.02] between the NAM (M = 
16.63, SEM = 2.24) and vehicle-treated groups (M = 11.62, 
SEM = 0.62). Therefore, injured animals treated with chronic 
infusions  of  NAM  had  higher  serum  NAM  levels  than  the 
injured animals treated with vehicle. The NAD blood serum 
level analysis revealed no overall significant differences between 
groups F(2,20) = 0.46, p = 0.64; however, there was a differ-
ences between the NAM (M = 9.63, SEM = 3.82) and vehicle-
treated groups (M = 6.10, SEM = 1.60 (see Fig. 1).
Bilateral tactile removal. Latency to remove the tactile stim-
uli (adhesive patches) was analyzed in a 3 x 6 mixed ANOVA. 
The factors were group (NAM-treated, vehicle-treated and sham) 
x day (1–6). Latency to remove the contralateral patch was not 
significantly  affected  by  days  F(4.44,88.73)  =  1.61,  p  =  0.17. 
The group by day interaction was also not statistically signifi-
cant F(8.87,88.73) = 0.96, p = 0.48. However, the main effect 
of group was statistically significant, F(2,20) = 4.55, p = 0.02. 
The chronic infusion of NAM significantly reduced the removal 
latencies in lesioned animals (see Fig. 2). Fischer’s LSD pairwise 
comparisons revealed significant differences in removal latencies 
between the NAM-treated group and the vehicle-treated group 
on days 2 (LSD(15) = 44.50, p = 0.006), 4 (LSD(15) = 32.63, 
p = 0.04) and 6 (LSD(15) = 36.44, p = 0.01). No significant 
injury-induced impairments in patch removal were seen on the 
left forelimb p > 0.05.
Locomotor placing. Foot-faults on the grid floor were ana-
lyzed in a 3 x 6 mixed ANOVA. The factors were group (NAM-
treated,  vehicle-treated  and  sham)  x  day  (1–6).  The  number 
of foot-faults was significantly affected by days F(3.76, 75.11) 
= 3.22, p = 0.001 and group, F(2, 20) = 63.17, p = 0.001 (see 
Fig. 3). However, the interaction was not statistically significant 
F(7.51, 75.11) = 0.57, p = 0.79. Pairwise comparisons revealed 
significant differences in foot-faults between the NAM-treated 
group and the vehicle-treated group on days 2 (LSD(15) = 24.63, 
p = 0.008), 4 (LSD(15) = 35.04, p = 0.001), 6 (LSD(15) = 28.25, 
p = 0.005), 8 (LSD(15) = 22.91, p = 0.001), 14 (LSD(15) = 16.16, 
p = 0.01) and 28 (LSD(15) = 31.20, p = 0.001).
Limb-use asymmetry. The percentage of bias towards use 
of  the  contralateral  forelimb  was  analyzed  in  a  3  x  3  mixed 
following injury.8 In addition, continuous delivery of progester-
one by silastic capsules following TBI has been shown to reduce 
anxiety.9 All of these studies demonstrated significant treatment 
effects; however, few studied the effect on recovery of function 
following injury. These studies used subcutaneous infusions as 
a  clinically  relevant  route  of  administration  since  continuous 
intravenous infusion in rodents is problematic. Therefore, these 
studies could not conclude whether continuous infusions result 
in prolonged and enhanced recovery of function following TBI.
A promising preclinical treatment for TBI is nicotinamide 
(NAM),  a  neuroprotective  soluble  B-group  vitamin.10-17  The 
administration of an i.p. dose of NAM (500 mg/kg) administered 
15 minutes and 24 hours post-TBI, resulted in significant behav-
ioral and anatomical recovery following bilateral frontal injury.10 
Using the same dosing regimen, NAM was able to prevent blood-
brain barrier (BBB) breakdown and reduce apoptosis at 5, 24 and 
72 hours post injury following unilateral CCI.12 In a model of 
fluid percussion injury (FPI), 2 doses of 50 or 500 mg/kg NAM 
administered within 24 hrs of injury, induced sensorimotor and 
cognitive recovery up to thirty-five days post injury15 and pro-
vided significant acute neuroprotection in the injured cortex 24 
hours post-FPI.11 The window of opportunity for NAM treat-
ment (50 mg/kg, i.p.) has been shown to extend to 4–6 hours 
post-TBI in the bilateral frontal CCI model on both sensorimotor 
and cognitive measures and in some cases can be effective up to 
24 hrs post-TBI on sensorimotor behaviors in a unilateral CCI 
model.13-14 However, no previous studies have examined whether 
NAM is beneficial following continuous administration. Future 
clinical studies with NAM will likely utilize continuous infusions 
Figure 1. Continuous infusion of nicotinamide (NAM) significantly 
elevated serum NAM but not NAD+ levels following cortical contusion 
injury (CCI). plotted are the mean (+seM) blood serum levels (µg/mL) of 
NAM and NAD+ determined by hpLC for the NAM-treated, vehicle-treat-
ed, and sham animals collected following 7 days of continuous infusion 
of NAM (50 mg/kg/day, s.c. minipump). NAM was significantly elevated 
(*p < 0.05) compared to vehicle; whereas, NAD+ levels were only slightly 
elevated.www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  147
ANOVA. The factors were group (NAM-treated, vehicle-treated 
and sham) x day (1–3). The percentage of contralateral forelimb 
bias was not statistically significantly affected by day, F(2,40) = 
0.75, p = 0.48. The interaction between day and group was also 
not statistically significant, F(4,20) = 1.04, p = 0.40. However, 
the group factor was statistically significant F(2,20) = 32.90, p 
= 0.001 (see Fig. 4). Pairwise comparisons revealed significant 
differences in contralateral biases between the NAM-treated and 
vehicle-treated groups on day 4 [LSD(15) = 11.32, p = 0.04], 
15 [LSD(15) = 15.78, p = 0.007] and 28 [LSD(15) = 11.33, p = 
0.05]. Therefore, chronic administration of NAM significantly 
reduced the bias towards the contralateral forelimb.
Lesion analysis. An initial one-way ANOVA was performed 
on the volume of the intact contralateral cortex. Three groups 
were  used  in  this  analysis  (NAM-treated,  vehicle-treated  and 
sham). There was not a significant difference in contralateral 
cortical volume between the groups, F(2,20) = 2.36, p = 0.12. 
A second, one-way ANOVA was used to analyze the percentage 
of cortex volume reduction in the contralateral hemisphere com-
pared to the ipsilateral hemisphere. There was a significant lesion 
effect between the groups, F(2,20) = 80.84, p = 0.001 (see Fig. 
5). Pairwise comparisons revealed significant differences in cor-
tex reduction (LSD(15) = 6.38, p = 0.01) between the NAM (M = 
21.91, SEM = 1.45) and vehicle-treated groups (M = 28.29, SEM 
= 2.33). Therefore, lesioned animals treated with chronic infu-
sions of NAM had significantly lower percentage of reduction in 
the contralateral cortex than the lesioned animals treated with 
vehicle. Representative histology sections are shown in Figure 6.
Discussion
The purpose of this study was to examine the preclinical efficacy 
of continuous treatment with NAM following TBI. The preclini-
cal efficacy of NAM following TBI has been well established for 
bolus administrations; however, it is of clinical interest to deter-
mine if sustained, continuous infusion of NAM also demon-
strates preclinical efficacy.
The  sensorimotor  testing  on  the  bilateral  tactile  adhesive 
removal test following unilateral CCI of the SMC resulted in 
strong initial injury impairments in the vehicle-treated animals. 
In contrast, continuous infusion of NAM resulted in a signifi-
cant reduction in the initial magnitude of the behavioral defi-
cit and facilitation in recovery of function. On the locomotor 
placing test, unilateral CCI produced enduring deficits in the 
vehicle-treated animals. Infusion of NAM significantly reduced 
the magnitude of the initial placing deficit; in fact, NAM-treated 
animals were significantly less impaired on every test day com-
pared to the vehicle-treated animals. On the forelimb asymmetry 
test CCI produced very enduring deficits in the vehicle-treated 
animals. On all test days (4, 15 and 28 days) post-injury the vehi-
cle-treated animals showed a forelimb bias favoring the unim-
paired forelimb that was greater than 80%. In contrast, the sham 
controls showed virtually no bias and used both the ipsilateral 
and contralateral forelimbs equally. The animals treated with 
infusion of NAM demonstrated a significant reduction in their 
bias toward the unimpaired limb on each test day compared to 
Figure 2. Continuous infusion of nicotinamide (NAM) significantly 
improved recovery on the bilateral adhesive removal test following cor-
tical contusion injury (CCI). The graph shows the plotted mean (+seM) 
of the tactile stimuli removal latencies for all three experimental groups 
(NAM-treated, vehicle-treated and sham) following unilateral CCI. seven 
days of continuous infusion of NAM significantly improved performance 
compared to vehicle (*p < 0.05). There were no statistically significant 
differences between the NAM-treated and sham animals.
Figure 3. Continuous infusion of nicotinamide (NAM) significantly 
improved recovery on the locomotor placing test following cortical 
contusion injury (CCI). The graph shows the plotted mean (+seM) of the 
percentage of foot-faults on the grid for all three experimental groups 
(NAM-treated, vehicle-treated, and sham) following unilateral CCI. 
seven days of continuous infusion of NAM significantly improved loco-
motor placing performance compared to vehicle (*p < 0.05). Although, 
a significant treatment effect was seen with NAM compared to vehicle 
in the injured animals.148  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
the vehicle-treated animals. Together, all of the behavioral data 
in this study suggest that a 7-day regimen of low dose NAM sig-
nificantly improved recovery of function following TBI.
The behavioral data as a whole in this study replicate and 
extended the beneficial effects we have seen with bolus admin-
istrations of NAM following CCI and fluid percussion injury 
(FPI) on a multitude of behavioral measures, including motor, 
sensorimotor and cognitive tests.10,13-15 In the present study direct 
comparison between bolus administrations of NAM and contin-
uous administration of NAM were not performed, so experimen-
tally, it cannot be determined if the continuous infusions were 
better than the bolus route. However, some speculations can be 
made. The current continuous infusion findings are consistent 
with a previous study in which bolus administrations of NAM 
(50 mg/kg) were performed daily for 5 days post-CCI.13 On the 
bilateral tactile removal test, animals receiving injections at 15 
minutes or 4 and 8 hours post-CCI showed recovery over time, 
with the best recovery shown in the 15 minute group. However, 
in  the  current  study,  the  NAm-treated  group  demonstrated 
a greater degree of initial injury reduction on day 2 post-CCI.   
A strong initial reduction in magnitude of the tactile removal 
deficit has also been shown following 12 days of bolus injections 
of 50 mg/kg NAM.14 However, in that paper animals did not start 
to perform at sham control levels until day 14 post-CCI; whereas, 
in the current study NAM-treated animals were performing at 
sham levels on day 2. A similar effect was also seen on the loco-
motor placing test. Bolus injections of NAM administered for 12 
day starting 4 hours post-CCI resulted in the animals perform-
ing at sham control levels.14 When treatment was initiated 8 and 
24 hours after injury, the animals did not perform at sham lev-
els, but were lower than vehicle-treated animals.14 In the present 
study, animals treated with NAM favored the use of their con-
tralateral forelimb significantly less than vehicle-treated animals. 
A similar finding showing that NAM treatment when started at 
4 or 8 hours post-CCI demonstrated a significant reduction in 
contralateral forelimb bias has been reported.14 Thus, the results 
from the current study continue to support the preclinical effi-
cacy of NAM for TBI. However, in our experience the beneficial 
behavioral effects we saw in the current study are some of the 
strongest we have observed in these animals models.
The data from the lesion analysis also revealed a significant 
improvement in tissue integrity. Infusion of NAM significantly 
reduced the size of the injury, as measured by a cortical volume 
analysis. The vehicle-treated group had an average reduction in 
frontal cortical volume of 28.3% compared to the NAM-treated 
group that showed a reduction of 21.9%. This cortical protective 
effect is similar to those effects we have seen in previous stud-
ies.10,11,13-16 Furthermore, previous studies in our laboratory have 
shown NAM to significantly reduce apoptosis, GFAP expression, 
edema and neuronal death.11,12,16 Thus, it is likely that by reduc-
ing the pathophysiological events associated with CCI in previ-
ous studies that NAM resulted in the beneficial behavioral effects 
observed in the current study.
We have previously demonstrated that systemic administration 
of NAM elevated serum NAM concentrations.13,15 The data from 
the current study confirmed that sustained, low-level delivery of 
Figure 4. Continuous infusion of nicotinamide (NAM) significantly 
improved recovery on the forelimb asymmetry test following cortical 
contusion injury (CCI). The graph shows the plotted mean (+seM) of the 
percent forelimb bias for all three experimental groups (NAM-treated, 
vehicle-treated and sham) following unilateral CCI. The no bias line 
indicates the point at which the ipsilateral and contralateral forelimbs 
are being used equally. seven days of continuous infusion of NAM 
significantly improved performance compared to vehicle. Although, a 
significant treatment effect was seen with NAM compared to vehicle in 
the injured animals, there were still enduring deficits compared to the 
sham controls.
Figure 5. Continuous infusion of nicotinamide (NAM) significantly 
limited cortical injury following cortical contusion injury (CCI). plotted 
are the mean (+seM) percentages of cortical volume reductions in the 
NAM-treated animals, vehicle-treated animals, and sham animals. NAM 
significantly reduced the extent of the cortical injury compared to 
vehicle (*p < 0.05).www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  149
Interestingly, there were lower levels of NAD+ at 7 days follow-
ing injury in the vehicle-treated animals compared to the sham 
controls; furthermore, treatment with NAM appeared to have 
NAM for 7 days also increased serum NAM levels significantly. 
Serum NAD+ levels were also analyzed and no such significant 
elevation was seen in the blood following NAM administration. 
Figure 6. Representative histology showing that continuous infusion of nicotinamide (NAM) significantly improved recovery on the forelimb asymme-
try test following cortical contusion injury (CCI). Unilateral CCI produced marked cortical cavitation. shown are representative images of the effect of 
NAM infusion and vehicle treatment through the extent of the injury (0.44x) at coordinates +1.00, 0.00 and -1.00 mm relative to bregma. Measurement 
bar = 2.0 mm.150  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
there is some concern that NAM therapy may be a double-edged 
sword when treating oxidative or metabolic conditions, especially 
in the aged populations.19,20 Current studies in our laboratory 
are examining the ability of NAM to be neuroprotective in aged 
animals.
In  conclusion,  the  current  study  showed  that  unilateral 
SMC  injury  produced  relatively  enduring  behavioral  deficits 
on a variety of forelimb sensorimotor tasks. Sustained deliv-
ery of NAM throughout the first 7 days post-injury resulted 
in significant improvements in these behavioral deficits. Future 
studies will be aimed at maximizing NAM administration by 
providing sustained, steady-state levels of treatment with NAM 
post-TBI.
Methods
Animals.  Twenty-three  male  Sprague-Dawley  rats  were  used 
for this study and weighed an average of 369.60 g (SEM 7.42) 
at the time of injury and pump implantation. A single animal 
in the sham group died during recovery and was not replaced. 
The experimental procedures conducted within this study were 
reviewed and approved by the Institutional Animal Care and Use 
Committee and the study was conducted in a facility certified 
by the American Association for the Accreditation of Laboratory 
Animal  Care.  Animals  were  individually  housed  in  standard 
cages and allowed ad lib access to food and water. A twelve hour 
light:dark cycle was used. Rats were handled daily for approxi-
mately one week before surgery. Behavioral testing took place 
during the light cycle.
CCI  surgery.  Surgical  procedures  were  based  on  previous 
studies13,14 and performed under aseptic conditions. Animals were 
anesthetized with a combination of Isofluorane (2–4%) and oxy-
gen (0.8 L/minute) and placed on a heated surgical stage (37°C) 
in a stereotaxic frame. A unilateral CCI over the left sensorimotor 
cortex or sham procedure was then performed. A midline inci-
sion was made through the skin and underlying fascia. A cran-
iotomy measuring 5.0 mm in diameter was created using a motor 
tool. A specially designed drill bit was used to prevent damage to 
the meninges and cortex. The craniotomy was positioned at Ap 
= 0.0, ML = +2.5. The cortical region containing the sensorimo-
tor cortex (forelimb region) was then exposed. A sterile, stainless 
steel impactor tip with a 4.0 mm diameter was used to create 
the injury. The tip was attached to an electromagnetic impactor 
(www.myneurolab.com) and situated at a 10 degree angle. The 
tip made impact with the cortex at a velocity of 2.75 m/s for 0.5 
seconds. A 2.0 mm compression of the cortex occurred. After 
injury, bleeding was controlled and incisions were sutured closed. 
Afterwards, animals were placed in a heated recovery cage until 
locomotion returned. Sham procedures were the same, except 
cortical impact did not occur.
Drug administration. Twelve hours prior to surgery, Alzet 
osmotic mini-pumps (model 2001; delivery rate of 1 µL per 
hour for 7 days) were primed and loaded with a concentra-
tion of NAM (625 mg of NAM dissolved per 1 mL of 0.9% 
PBS) or 0.9% PBS. The pumps were then incubated overnight. 
Approximately  thirty  minutes  after  CCI,  the  osmotic  mini-
partially offset this reduction. One factor that may have limited 
our ability to see significant changes in serum NAD+ levels is 
the fact that blood was collected 7 days post-TBI, it might be 
expected that larger injury-induced decreases in serum NAD+ 
could be observed in the acute, early phases after injury. A recent 
article  has  shown  that  administration  of  a  poly(ADP-ribose) 
polymerase inhibitor (PARP) prevented NAD+ depletion in the 
injured cortex acutely following TBI.18 Thus, it is likely that a 
time course analysis of the tissue might reveal different results 
from those gathered with the serum analysis and it is not known 
how cortical levels of NAD+ correlate with serum levels. A study 
investigating this relationship is currently being conducted.
NAM  has  been  shown  to  be  a  broad  spectrum  neuropro-
tectant,  which  is  mechanistically  multi-dimensional,  and  has 
expanding avenues into a variety of health conditions.19-21 NAM 
has shown promise experimentally as a poly (ADP-ribose) poly-
merase (PARP) inhibiter21-23 and has shown increases in cell sur-
vival, adenosine triphosphate (ATP) and NAD+ levels as well.24-26 
NAM also has a role as an essential precursor for the coenzyme 
NAD+.27 NAM is able to maintain levels of PARP therefore sup-
plying neuronal preservation and energy. NAM is able to reach 
peak levels within the brain fairly quickly and therefore readily 
increase NAD+ and ATP brain stores via a specific uptake mecha-
nism.28 NAM can be used to alleviate two detrimental cascades 
after injury: elevate NAD+ thereby restoring ATP levels and to 
serve as a PARP inhibitor, also restoring ATP.22 Using NAM to 
elevate NAD+ levels in conjunction with PARP inhibition are 
additive in respect to ATP restoration and has proven to be more 
beneficial.29 Additionally, NAM is critical for synthesizing nico-
tinamide adenine dinucleotide phosphate (NADP+), modulating 
cellular metabolism, plasticity, longevity, inflammatory micro-
glial responses, and maintenance of the internal and external 
cellular environment.27,30 Recently, new cellular pathways have 
emerged that appear to govern the beneficial actions of NAM in 
disease conditions and have recently been reviewed.20 These path-
ways include forkhead transcription factors and the sirtuins.19,20 
NAM also activates protein kinase B and inhibits transcription 
of proapoptotic genes. A downstream effect of protein kinase B is 
closing of the mitochondrial transition pores opened by excessive 
Ca²+ influx. The mitochondrion is able to regain ionic homeo-
stasis and bring cytochrome C back to physiological conditions 
thereby inhibiting caspase 9 mediated cell death.20,27
In our experience with NAM therapy for experimental TBI 
we have not observed any detrimental effects of treatment at 50 
or 500 mg/kg.10-17 These studies have included daily dosing r 
egimens of NAM (50 mg/kg) for 7 and 14 days.13,14 In the current 
study, continuous infusion of NAM did not result in any overtly 
observable detrimental effects. Currently, NAM is used clinically 
in the treatment of pellagra (nicotinamide deficiency) and dia-
betes. Doses less than 600 mg/kg have been used daily for up to 
several weeks in studies using rats without complications, but the 
at higher doses liver and kidney damage have been reported.26 
For treatment of various diseases in the human population, daily 
doses of 1 to 12 grams have been used.31 Drug safety tests indi-
cate that daily doses up to 3 grams can be used long-term safely 
and without side effects.31 However, a recent reports suggests that www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  151
samples were separated with a microcentrifuge and stored frozen 
at -80°C. NAM was analyzed in serum using HPLC with UV 
detection at 254 nm on a Varian Pro Star 210 HPLC system using 
a modification of a previously developed assay used to measure 
NAD.34 Briefly, 60 µL serum samples and the added internal 
standard, nicotinamide hypoxanthine dinucleotide sodium salt 
(de-amino NAD), were deproteinized with 1 M perchloric acid, 
buffered with 1 M potassium phosphate pH 7.5, and centrifuged. 
The supernatant was injected onto a Adsorbosil C-18, 5 um,   
250  x  4.6  mm  column  (Grace  Davison  Discovery  Sciences, 
Deerfield, IL) and separated using a mobile phase gradient of 
6% to 20% methanol over 10 mins in 0.2 M ammonium phos-
phate at pH 5.25. The de-amino NAD eluted at 6.3 minutes 
and NAM eluted at 13.5 mins.
Histology. Twenty-eight days after CCI, animals were anes-
thetized with a lethal dose of urethane (3.0 g/kg, i.p.). Once an 
absence of the pedal reflex response occurred, animals followed 
by 10% phosphate buffered formalin (PBF). Once the brain 
was removed from the skull, they were post-fixed in PBF for 24 
hours. Brains were then cryoprotected in a 30% sucrose solution 
for three days prior to frozen sectioning. Serial coronal sections   
(40 µm thick) were taken using a sliding microtome and a 
freezing stage. The sections were then collected into a cryo-
preservative solution, stored and then frozen.
Lesion analysis. The coronal sections were mounted on gel-
atin-subbed microscope slides and stained with cresyl violet to 
determine the extent of lesion cavity formation. An Olympus 
microscope (BX-51) with an Olympus 13.5 megapixel digi-
tal camera (DP-70) attached to it was used to capture images 
of four sections thoroughly traversing the lesion cavity (1.60, 
0.70, -0.40, -1.60 relative to bregma).35 The Calvalieri method 
was used to calculate the volume of the ipsilateral and con-
tralateral cortex.36 The number of sections analyzed and their 
respective thickness (40 µm) were multiplied by the mean area 
of the lesion cavity. The extent of cortical injury was calcu-
lated using the formula [100 - (ipsilateral cortex volume/con-
tralateral cortex volume)*100]. This formula calculated the 
percent reduction in the ipsilateral cortex.
Data analysis. All behavioral testing and histological analy-
ses were performed without knowledge of treatment parameters. 
pumps were implanted (subcutaneous, s.c.). Briefly, under gas 
anesthesia an incision was made just posterior to the shoulder 
blades. After the incision was made, the underlying fascia and 
connective tissue was separated from the skin and the osmotic 
mini-pump was placed within the “pocket.” Afterwards, the 
incision was sutured closed. The osmotic mini-pumps deliv-
ered the NAM or vehicle at a rate of 50 mg/kg per day for 
seven days following CCI, based on the weight of the animal 
at the time of injury. On day seven the animals were again 
anesthetized and the pumps were removed and blood was col-
lected from the tail vein for NAM and NAD+ serum analy-
sis. There were three groups. Group 1 received CCI and was 
treated with an osmotic mini-pump containing NAM (NAM-
treated; n = 8). Group 2 also received CCI and was treated with 
an osmotic mini-pump containing the vehicle solution (0.9% 
PBS; vehicle-treated; n = 8). Group 3 received sham procedures 
and an osmotic mini-pump containing vehicle solution (sham;   
n = 7). See Table 1.
Bilateral  tactile  removal.  In  order  to  test  somatosensory 
function this test was administered on pre-injury day 2 and 
post-CCI days 2, 4, 6, 8, 14 and 28.13,14 Small adhesive patches 
(approximately 113.0 mm2) were applied to the radial aspects 
of each forelimb. The animal was then returned to their home 
cage. The latency for removal of the patch was recorded for 
each forelimb and was recorded with a stopwatch. A trial ended 
after both patches were completely removed or 120 seconds 
elapsed. Animals received two trials per test day. The latency to 
remove the adhesive patch from the contralateral forelimb was 
the dependent variable of interest.
Locomotor placing. In order to assess recovery of coordinated 
locomotor forelimb movement, this test was administered on pre-
injury day 2 and post-CCI days 2, 4, 6, 8, 14 and 28.14,15 On each 
test day, rats were placed on an elevated grid floor (56.0 x 54.0 
cm) and allowed to explore for three minutes. There were open-
ings measuring 3.5 cm2 in size on the grid floor. A “foot-fault” 
occurred when a rat inaccurately placed the forelimb through 
these openings. Rats were administered one trial per test day. The 
number of contralateral and ipsilateral forelimb “foot-faults” was 
the dependent variable. The following equation was used to cal-
culate the percentage of contralateral foot-faults: {[(Contralateral 
foot-faults-ipsilateral  foot-faults)/number  of  steps  during  the 
trial]*100}.
Limb-use asymmetry. To assess recovery of impaired (contral-
ateral) forelimb use, this test was administered on post-CCI days 
4, 15 and 20.14,32 Rats were placed in a clear observation chamber 
(20 cm x 20 cm x 30 cm) with four vertical surfaces. Animals 
were given a single five minute trial on each test day and allowed 
to place their paws on the vertical surface. The number of ipsi-
lateral and contralateral paw placements on the vertical surface 
was the dependent variable. The following equation was used to 
calculate the percent forelimb bias: {[ipsilateral paw placements 
+ (both paw placements at once/2)]/[ipsilateral + contralateral + 
both paw placements]*100}.33
NAM and NAD + analysis. These methods were based on pre-
vious studies.22,23 Immediately following removal of the pumps, 
blood samples were collected from the animals’ tail vein. The 
Table 1. experimental groups and timeline
Groups Condition n’s
Group 1 CCI + NAM 8
Group 2 CCI + Vehicle 8
Group 3 sham + Vehicle 7
Timeline
handling and pre-testing Days -7 to 0
surgery Day 0
pump Implantation 30 minutes 
Bilateral adhesive removal test Days 2, 4, 6, 8, 14, 28
Locomotor placing test Days 2, 4, 6, 8, 14, 28
Forelimb asymmetry test Days 4, 15, 20
perfusion Day 28152  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
procedure used. One-way ANOVA’s were calculated on the serum 
levels  and  anatomical  data  and  were  followed  by  appropriate   
post-hoc (LSD) analyses. Statistical significance was determined 
with a p value less than 0.05.
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Means and standard error of the means (SEM) were calculated for 
all data. The General Linear Model (GLM) ANOVA procedure 
with the repeated measures option was used to evaluate the effects 
of chronic NAM treatment across days. The groups included in 
the analysis were NAM-treated, vehicle-treated and sham. The 
between groups factor was treatment group assignment and the 
within groups factor was day of testing. The Huynh-Feldt cor-
rection was used to correct for repeated measures. Fischer’s Least 
Significant Different (LSD) test was the pairwise comparison 
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